Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002678 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Multiple Myeloma
A Phase 3 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 595
- Enrollment target
NCT00002678 is a Phase 3 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 595 participants.
The verdict
NCT00002678, a Phase 3 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 595 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients with multiple myeloma.
Interventions
- DRUG prednisone
- DRUG dexamethasone
- DRUG melphalan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 1995-06-02 |
| Est. Completion | 2009-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002678
The ClinicalTrials.gov registry entry for NCT00002678 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 595 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00002678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002678 about?
NCT00002678 is a clinical study titled "Combination Chemotherapy in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with multiple myeloma. PU...
What is the current status of trial NCT00002678?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 595 participants. The study started on 1995-06-02. Estimated completion is 2009-12-21.
What interventions are being tested in trial NCT00002678?
The interventions under investigation include: prednisone (DRUG), dexamethasone (DRUG), melphalan (DRUG).
Who is sponsoring clinical trial NCT00002678?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.